Melissa Lamb, APRN
Family · Newport, TNNPI 1013998038
Payments from drug & device makers
Across 286 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$814
- Novo Nordisk$740
- GSK$481
- AstraZeneca$326
- Pfizer$294
- Otsuka America Pharmaceutical, Inc.$173
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $814 |
| Novo Nordisk | 51 | $740 |
| GSK | 44 | $481 |
| AstraZeneca | 18 | $326 |
| Pfizer | 20 | $294 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| Astellas Pharma US Inc | 6 | $160 |
| E.r. Squibb & Sons, L.L.C. | 8 | $127 |
| Lundbeck LLC | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $91 |
| Neurocrine Biosciences, Inc. | 5 | $90 |
| Dexcom, Inc. | 4 | $86 |
| Bayer | 4 | $63 |
| Amgen | 4 | $62 |
| Alkermes, Inc. | 3 | $58 |
| Abbott | 3 | $56 |
| Axsome Therapeutics, Inc. | 3 | $49 |
| Lilly USA, LLC | 3 | $48 |
| Mylan Specialty L.p. | 3 | $46 |
| Johnson & Johnson | 3 | $45 |
| Esperion Therapeutics, Inc. | 3 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| UCB, Inc. | 1 | $35 |
| Merck | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Gilead | 1 | $22 |
| Argenx US, Inc. | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Biowound Solutions, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$4,496 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 123 | $145,433 |
| OzempicSemaglutide | 86 | $136,856 |
| MounjaroTirzepatide | 97 | $125,699 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 40 | $65,165 |
| XifaxanRifaximin | 20 | $62,590 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $54,118 |
| EliquisApixaban | 43 | $50,124 |
| LinzessLinaclotide | 32 | $45,903 |
| Repatha SureclickEvolocumab | 55 | $39,190 |
| KerendiaFinerenone | 35 | $37,399 |
| TrulicityDulaglutide | 34 | $33,294 |
| Spiriva HandihalerTiotropium Bromide | 32 | $33,077 |
| FarxigaDapagliflozin Propanediol | 26 | $29,350 |
| VraylarCariprazine Hcl | 18 | $26,600 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $19,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $48 | $158,993131 claims |
| Boehringer IngelheimJardiance | $27 | $145,433123 claims |
| Novo NordiskOzempic | $740 | $136,85686 claims |
| AbbVieLinzess, Vraylar, Synthroid | $814 | $74,26775 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $481 | $66,89062 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $106 | $62,59020 claims |
| PfizerEliquis | $294 | $50,12443 claims |
| BayerKerendia | $63 | $37,39935 claims |
| AstraZenecaFarxiga | $326 | $29,35026 claims |
| Johnson & JohnsonXarelto | $45 | $11,89011 claims |
| MerckBelsomra | $33 | $10,76321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Newport
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.